Bain Capital Public Equity Management Ii, LLC Arcus Biosciences, Inc. Transaction History

Bain Capital Public Equity Management Ii, LLC

  • $1.99 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$17.23 - $37.73 $666,542 - $1.46 Million
-38,685 Reduced 20.62%
148,887 $3.77 Million
Q1 2022

May 16, 2022
SELL
$28.92 - $41.83 $6.8 Million - $9.84 Million
-235,193 Reduced 55.63%
187,572 $5.92 Million
Q4 2021

Feb 14, 2022
SELL
$31.38 - $48.47 $1.01 Million - $1.56 Million
-32,098 Reduced 7.06%
422,765 $17.1 Million
Q3 2021

Nov 15, 2021
BUY
$26.93 - $37.68 $12.2 Million - $17.1 Million
454,863 New
454,863 $15.9 Million

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.5M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.02B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Bain Capital Public Equity Management Ii, LLC Portfolio

Follow Bain Capital Public Equity Management Ii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email